The revolution in prostate cancer discovery and treatment began in the late 1980s and 1990s with the discovery of PSA (prostate-specific antigen), whose elevated values in the blood most likely indicate the existence and progression of the disease (levels rise with increasing cancer mass) [12–20]. This evidence concerns the gene KLK3 and prostate carcinoma.